Restoration of renal function after prolonged allograft artery occlusion by thrombolysis

Jitendra Rathod1, Dinesh Upadhayay1, Jagdish Modhe2 and Rasika Sirsat1

1 Department of Nephrology 2 Department of Radiology, P. D. Hinduja National Hospital, and Medical Research Centre, Mahim, Mumbai, India

Thrombosis of the main renal allograft artery is a rare complication. Experimentally, the tolerance of animal kidneys to normothermic ischaemia appears to range from 1 to 2 h [1]. However, the safe limit for revascularization in allograft kidney following thrombotic occlusion does not correlate with the experimental findings. Recovery of renal function as late as 39 days after revascularization of renal arteries in native human kidneys has been reported [2]. We report a similar case.

Case.

A 27-year-old female had been undergoing haemodialysis for renal failure because of membranoproliferative glomerulonephritis (type I). She underwent a live unrelated renal transplant in January 1998 and was given conventional triple immunosuppression therapy (cyclosporin, azathioprin and prednisolone). The allograft function commenced immediately with a stable serum creatinine of 1.4 mg/dl. On the second post-operative day, she developed an abrupt onset of anuria. Patency of the bladder catheter was verified, a fluid challenge and diuretic was given to which she was unresponsive. An urgent colour doppler study and isotope scan of the renal allograft was done which revealed absence of flow in the renal artery and renal cortex. A percutaneous transfemoral renal allograft angiography was done which revealed a total thrombotic occlusion at the anastomotic site (Figure 1Go). Immediately intra-arterial thrombolysis was carried out with small bolous doses (50000 U) of urokinase amounting to a total of 0.2 million units. Post thrombolysis angiography showed excellent intrarenal blood flow (Figure 2Go). There was no systemic or operative site bleeding following thrombolysis. The duration of normothermic ischaemia sustained by renal allograft was 5 h resulting in ATN. Immunosuppression was modified by introduction of anti-CD3 monoclonal antibody (Mab) (5 mg/day), mycophenolate mofetil (0.25 g/day). Cyclosporin was withdrawn and azathioprin was omitted due to thrombocytopenia. The oliguric phase of ATN lasted for 10 days, during which she was haemodialysed. The patency of renal artery and blood flow was assessed by colour doppler of renal artery and isotope renal scan. Allograft function was monitored bi-weekly. She was discharged 1 month post transplant with a stable serum creatinine of 4.8 mg/dl. Twelve months post transplant she has a stable serum creatinine of 2.1 mg/dl and is on immunosuppression with cyclosporin (175 mg/day), mycophenolate mofetil (0.75 g/day) and prednisolone (10 mg/day).



View larger version (111K):
[in this window]
[in a new window]
 
Fig. 1. Thrombotic occlusion of allograft renal artery.

 


View larger version (127K):
[in this window]
[in a new window]
 
Fig. 2. Post thrombolysis revascularization of renal artery.

 
Comment.

Blood flow to native kidneys following renal artery occlusions may be maintained through collateral connections from ureteric or capsular blood vessels. Development of similar collateral blood flow to renal allograft is unlikely in the early post transplant period [3,4].

The incidence of allograft renal artery thrombosis varies from 1.4 to 3.5% [3,5]. Four cases of allograft renal artery thrombosis with partial recovery of renal function after an ischaemic insult of 2–12 h in the post transplant period have been reported [3,4,6]. In all these patients revascularization was achieved by surgical re-exploration. Recovery of renal function after successful revascularization of occluded renal artery by use of intra-arterial thrombolytic therapy in native [7,8] as well as allograft kidney has been reported [9], but this was done in the late post transplant period. Use of thrombolytic therapy is contraindicated in the early post surgical period [10]. In our case though contraindicated at 72 h post operatively, a low dose of intra-arterial urokinase was effective for thrombolysis and was not associated with bleeding. The precise duration of ischaemia was 5 h and the oliguric period lasted for 10 days.

In conclusion, partial recovery of allograft renal function can be expected if reperfusion is established as early as possible after the onset of thrombotic occlusion in allograft renal artery. Low dose intra-arterial thrombolytic agent (urokinase) by percutaneous transfemoral route is effective and safe for revascularization of occluded allograft renal artery in post operative period.

References

  1. Madden JL. Renal artery and suprarenal aortic occlusion: an experimental study. Arch Surg 1968; 97: 853–858[ISI][Medline]
  2. Adovasio R, Pancrazio F. Acute thrombosis of renal artery: restoration of renal function after late revascularisation. In Vasa 1989; 18 (3): 239–241
  3. Lee HM, Mendez-Picon G, Pierce JC, Hume DM. Renal artery occlusion in transplant recipients. Am Surg 1977; 43: 186–192[ISI][Medline]
  4. Gerhad DF, Devin JB, Halasz NA, Collins GM. Transplant renal artery thrombosis. Arch Surg 1982; 117: 361–362[Abstract]
  5. Jordan ML, Cook CT, Cardella CJ. Ten years of experience with vascular complications in renal transplantation. J Urol 1982; 128 (4): 689–692[ISI][Medline]
  6. Okieye SE, Zincke M. Renal allograft salvage with prolonged early post transplant renal artery occlusion. J Urol 1983; 129 (6): 1217–1227
  7. Rangel-Abundis A, Olvera R, Cordero J et al. Postangioplasty renal artery thrombosis treated intraluminally with thrombolysis. Gaceta Medica de Mexico 1991; 127 (3): 253–256[Medline]
  8. Florio F, Petronelli S, Nardella M et al. Intra-arterial urokinase in the treatment of acute thrombosis of the renal artery. Radiologia Medica 1992; 84: 168–170[Medline]
  9. Zajko AB, Mclean GK, Grossman RA et al. Percutaneous transluminal angio- and fibrinolytic therapy for renal allograft stenosis and thrombosis. Transplantation 1982; 33: 447–450[ISI][Medline]
  10. Mollinoff Ruddon, Gilman. Anticoagulant, thrombolytic and antiplatelets. In: Goodman Gilmans eds. The Pharmacological Basis of Therapeutics. McGraw Hill, New York: 1996: 1351–1357




This Article
Extract
FREE Full Text (PDF)
Alert me when this article is cited
Alert me if a correction is posted
Services
Email this article to a friend
Similar articles in this journal
Similar articles in ISI Web of Science
Similar articles in PubMed
Alert me to new issues of the journal
Add to My Personal Archive
Download to citation manager
Disclaimer
Request Permissions
Google Scholar
Articles by Rathod, J.
Articles by Sirsat, R.
PubMed
PubMed Citation
Articles by Rathod, J.
Articles by Sirsat, R.